Profitelligence Profitelligence · Filing Ledger Open DXCM research →

Form 8-K · Current Report · Filed 2024-02-08

DexCom Reports Strong Q4 2023 Financial Results and Strategic Highlights

DexCom, Inc. reported a 27% growth in revenue for Q4 2023 to $1.03 billion, with notable strategic advancements including FDA submissions for new glucose sensors and pump connectivity integration. The company also reiterated its 2024 guidance with expected organic growth of 16-21%.

Filer
Dexcom Inc. DXCM · NASDAQ
Filed
Accession
0001093557-24-000020
CIK
0001093557
Signal
Low impactHealthcare

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$126.61

Next session

-4.8%

Since filing

-34.1%

Latest close

$83.45

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from DXCM reporting the same item, with the next session's move:

Exhibits (1)

About Dexcom Inc.

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.

Exchange NASDAQ Industry Medical Devices Company website ↗

Never miss another DXCM filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts